Skip to content
Screener

Teleflex TFX Interventional — Net revenues

Other product segments

Vascular
$246.34M+9.0%
Surgical
$112.12M+9.1%

Similar metrics at other companies

Haemonetics logo
HAEInterventional Technologies — Net revenues
$59.94M+2.5%
ROP
ROPProduct Revenue — Net revenues
$462.7M+7.7%
Travel + Leisure logo
TNLDeferred subscription revenue — Net revenues
$42M-2.3%
ROP
ROPTotal Software Revenue — Net revenues
$1.63B+12.4%
Travel + Leisure logo
TNLDeferred exchange-related revenue — Net revenues
$9M0.0%
Gen Digital Inc. logo
GENSubscription and service revenue — Net revenues
$1.33B+6.2%

Other financials

Income statement

See full
Revenue$570.3M+28.9%
Gross profit$331.7M+24.8%
Operating income$72.8M-20.1%
Net income$99.7M-18.7%
EPS (diluted)$2.28-17.7%

Balance sheet

See full
Cash & equivalents$316.9M+23.5%
Total debt$3.0B+49.5%
Total equity$2.9B-31.5%
Total assets$6.8B-8.0%

Cash flow

See full
Operating cash flow$91.9M+348%
CapEx$14.0M-49.5%
Free cash flow$77.9M+220%

Valuation

See full
Market cap$6.15B+24.1%
Enterprise value$8.81B+31.7%
P/S2.7×-0.1×

Profitability

See full
Gross margin46.7%-4.5pp
Operating margin2%-14.9pp
Net margin-45.8%-56.9pp
FCF margin7.9%

Returns & leverage

See full
Return on equity-28.9%-33.2pp
Debt / equity+0.6×
Current ratio2.6×+0.2×

Where this comes from

Reported directly by Teleflex in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Teleflex’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 3:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000096943-26-000095
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 29, 2025Six Months Ended / June 30, 2026Six Months Ended / June 29, 2025
Vascular$246,337$225,908$483,149$445,039
Interventional211,874113,853416,530214,004
Surgical112,121102,764218,915197,740
Net revenues (1)$570,332$442,525$1,118,594$856,783

Item 1. Financial Statements (Unaudited):

FAQ

What is Teleflex's interventional — net revenues?
Teleflex (TFX) reported interventional — net revenues of $211.87M in Q2 2026.
How has Teleflex's interventional — net revenues changed year-over-year?
Teleflex's interventional — net revenues increased by 86.1% year-over-year, from $113.85M to $211.87M.
What is the long-term trend for Teleflex's interventional — net revenues?
Over 4 years (2021 to 2025), Teleflex's interventional — net revenues has grown at a 6.7% compound annual growth rate (CAGR), from $427.5M to $554.22M.
What does interventional — net revenues mean?
This metric represents the total gross sales generated by the interventional medical device segment after accounting for returns, allowances, and discounts. It reflects the market demand and commercial performance of specialized products used in minimally invasive procedures, such as diagnostic and therapeutic catheters. Tracking this revenue stream provides insight into the company's competitive position and growth trajectory within the high-acuity interventional healthcare market.

Ask your AI about Teleflex's interventional — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude